Replies to post #2351 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

A good example for you is any of the RSV therapeutics- all failed. Great exposures and great potencies - no translation. My point is that just because something is potent and has good PK, that doesn’t mean it will translate into a cure for an acute infection.

That's your big example? Bbbbwwaaa hhhhaaaa. Nobody has YET shown ANY mechanism which can be used to successfully block or limit RSV in humans to prevent illness. In stark contrast, inhibiting the Covid protease is an ESTABLISHED mechanism of blocking Covid replication has been shown to be HIGH EFFECTIVE in HUMANS. That drug is Paxlovid. Are you going to dispute that? The levels of EDP-235 far exceed what is needed to inhibit Covid by the same mechanism as Paxlovid.

Remember, this is a phase 2 in standard risk, highly seropositive population with a safety primary endpoint. A very hesitant step, you must agree.

So? ENTA isn't a large pharma so they are spending less money on a phase 2 trials so they can partner for the phase 3. Would I prefer a phase 2/3? As an investor who wants to make money sooner rather than later, yes.

Just trying to be objective. And I’m not short anything.

You created an alias 3 days ago and all you have done is make a series of posts that are very questionable attacks on ENTA and you justify it with irrelevant comparisons to RSV. Either you never heard of Paxlovid and that its inhibition of the Covid protease is effective in humans. Well, either that or you have an agenda, i.e. a short.

[vinmantoo]

Again- where is the animal efficacy data? They must have it.

https://www.businesswire.com/news/home/20230314005318/en/Enanta-Pharmaceuticals-to-Present-New-Data-for-EDP-235-its-3CL-Protease-Inhibitor-in-Development-as-an-Oral-Once-Daily-Treatment-for-COVID-19-at-the-36th-International-Conference-on-Antiviral-Research